Cancer premiums and latency effects: A risk tradeoff approach for valuing reductions in fatal cancer risks
From MaRDI portal
Publication:928723
DOI10.1007/S11166-008-9032-2zbMath1136.91491OpenAlexW2008346906MaRDI QIDQ928723
Chris Dockins, Melonie B. Sullivan, George Van Houtven
Publication date: 11 June 2008
Published in: Journal of Risk and Uncertainty (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1007/s11166-008-9032-2
Cites Work
- A choice experiment approach to the valuation of mortality
- Willingness to pay for mortality risk reductions: does latency matter?
- Age, health and the willingness to pay for mortality risk reductions: A contingent valuation survey of Ontario residents
- The value of a statistical life: A critical review of market estimates throughout the world
- Effects of disease type and latency on the value of mortality risk
- A Reference Lottery Metric for Valuing Health
This page was built for publication: Cancer premiums and latency effects: A risk tradeoff approach for valuing reductions in fatal cancer risks
